BioreclamationIVT supports drug, diagnostic and vaccine research for infectious diseases

Published: 1-Aug-2017

BioreclamationIVT will now offers HIV-1, HIV-2, dengue, zika and malaria blood-derived biological samples to advance drug, diagnostic and vaccine development against these devastating diseases

BioreclamationIVT, a leading provider of biospecimens and related services has expanded its infectious disease-state portfolio to include frozen whole blood, plasma and serum samples from patients with HIV-1, HIV-2, dengue, zika and malaria infection. The HIV-1 collection includes samples from pediatric patients and pregnant women.

Clifford M. Raynor. Senior Vice President of Clinical Operations at BioreclamationIVT, said: “We are pleased to be able to provide biopharmaceutical companies with these vitally important biological samples that their researchers need to create diagnostics and develop therapeutic drugs and vaccines against these dreadful diseases.

"These biological samples are very hard to source because some of the diseases are seen predominantly in donors from underdeveloped countries.”

BioreclamationIVT has a network of more than 100 IRB approved clinics helping to locate and deliver a diverse array of important biological samples.

These clinics follow a very stringent donor screening and testing process. They also adhere to well-defined sample collection, storage and handling procedures to ensure sample consistency.

All of the biological samples are collected on site under medical supervision, processed and frozen according to a strict protocol, and shipped in a temperature-controlled container to ensure high quality products.

These new samples will become part of BioreclamationIVT’s infectious disease-state portfolio, which already includes biological material from patients with hepatitis B, hepatitis C, syphilis and chlamydia.

You may also like